Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509093 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00509093 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT00509093, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with newly diagnosed acute myeloid leukemia who have received chemotherapy.
Interventions
- GENETIC gene expression analysis
- GENETIC mutation analysis
- GENETIC polymerase chain reaction
- DRUG imatinib mesylate
- OTHER flow cytometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509093
The ClinicalTrials.gov registry entry for NCT00509093 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00509093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509093 about?
NCT00509093 is a clinical study titled "Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy". RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with newly diagnosed acute myeloid leukemia who have received chemotherapy.
What is the current status of trial NCT00509093?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2008-10. Estimated completion is 2015-04-09.
What interventions are being tested in trial NCT00509093?
The interventions under investigation include: gene expression analysis (GENETIC), mutation analysis (GENETIC), polymerase chain reaction (GENETIC), imatinib mesylate (DRUG), flow cytometry (OTHER).
Who is sponsoring clinical trial NCT00509093?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.